J Dedrick Jordan MD PhD (

Dr. Jordan of Duke University School of Medicine has no relevant financial relationships to disclose.

Caitlin Clark MD (

Dr. Clark of Duke University has no relevant financial relationships to disclose.

Matthew Lorincz MD PhD, editor. (

Dr. Lorincz of the University of Michigan received honorariums from Alexion for advisory board service.

Originally released August 3, 1994; last updated March 12, 2021; expires March 12, 2024


Hyponatremia is the most common electrolyte disorder in hospitalized patients (Adrogue 2000) and is associated with increased morbidity and mortality (Waikar et al 2009; Corona et al 2015). Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) is a leading cause of euvolemic hyponatremia in hospitalized patients (Upadhyay et al 2009). It occurs with an independent release of arginine vasopressin (also known as ADH) not in response to baroreceptor or osmole sensing receptor changes. Clinically, it is distinguished from other hyponatremic states by apparent euvolemia, as opposed to hypovolemic or fluid overload states. By labs, the urine appears inappropriately concentrated compared to the fluid status of the patient. SIADH is typically the clinical manifestation of another underlying disease state, most commonly malignancy, pulmonary disease, or central nervous system disease. Treatment of SIADH requires treatment of the underlying etiology for definitive management. Hyponatremia may be acutely corrected for symptom management while other diagnostic studies or treatments are underway.

Key points


• SIADH can only be diagnosed after excluding other forms of hyponatremia, adrenal insufficiency, and hypothyroidism.


• Most common etiologies of SIADH include malignancy, medications, CNS disorders, and pulmonary disorders.


• Hyponatremia is associated with increased morbidity and mortality.


• Urgency of sodium correction depends on acuity of hyponatremia and presence of symptoms.


• Some genetic mutations have been identified that lead to a syndrome of antidiuresis.


• Vasopressin antagonists can be considered for treatment, but controversy exists regarding dosing and strength of recommendation.


• Overcorrection of chronic hyponatremia may lead to osmotic demyelination.

Historical note and terminology

Hyponatremia has been described in association with pulmonary and central nervous system disease states since the 1930s. In 1957, Bartter and Schwartz published a description of 2 patients with bronchogenic carcinoma and hyponatremia in the setting of inappropriately high urine sodium content and euvolemia. In their study of these patients they identified that correction of serum sodium was achieved with fluid restriction (Schwartz et al 1957). They posited an inappropriate secretion of antidiuretic factor as the etiology of hyponatremia, and a decade later this became known as syndrome of inappropriate antidiuretic hormone and clinical criteria were described (Bartter and Schwartz 1967).

Science has now come to recognize that the etiologies of hyponatremia related to the vasopressin system go beyond abnormal secretion of the hormone and may include genetic mutations of receptors which respond to ADH. A broader term to include these etiologies is syndrome of inappropriate antidiuresis or SIAD. In this article, the terminology SIADH will be used.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology